Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

CD19-specific adapter molecule SWI019

A preparation of adapter molecules consisting of an antibody fragment (Fab) targeting CD19 linked to a 14 aa peptide epitope, or peptide neo-epitope (PNE), recognizable by CLBR001, that may be used to activate CLBR001. Upon administration of CD19-specific adapter molecule SWI019, and upon co-administration of CLBR001, the Fab moiety of SWI019 targets and binds to tumor cells expressing CD19, and the PNE of SWI019 binds to the binding domain of CLBR001, thereby activating CLBR001. This induces selective toxicity in and causes lysis of CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:alpha-CD19 Fab-based switch SWI019
anti-CD19 antibody SWI019
Code name:SWI 019
SWI-019
SWI019
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search